Platelet aggregation and ApoE genotypes in the Framingham Heart Study

The final primary sample included 3,169 participants (median [Q1, Q3] age, 55 [48, 61]; 54.2% women) of which 22.1% were on PMT. (Table 1). 716 (22.6%) were ApoE4 positive and 402 were E2 (16.4% of the sample after excluding E4). Being an ApoE4 carrier was not associated with platelet aggregation (β±SE: 0.41±1.05, P>0.05). ApoE2 was also not associated (-0.72±1.33, P>0.05) (Figure 1). No associations with the secondary outcomes or interactions with covariates were detected. No associations were observed in the external validation cohort (n = 2,469) CONCLUSION: Our results in a middle-aged cohort indicate that the ApoE genotypes (E2 and E4) are not associated with platelet aggregation. The pathways leading to increased vascular dysfunction in ApoE4 carriers may not involve platelet activity, at least in midlife.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2024-12-01
DOI
https://doi.org/10.1002/alz.092838
Primary Topic
Medication Adherence and Compliance
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Platelet aggregation and ApoE genotypes in the Framingham Heart Study

Sudha S. Seshadri, Matthew R. Scott, Luisa F Figueredo, Ricardo S. Osorio et al.
Alzheimer s & Dementia
Medication Adherence and Compliance
article

Platelet aggregation and ApoE genotypes in the Framingham Heart Study

Sudha S. Seshadri, Matthew R. Scott, Luisa F Figueredo, Ricardo S. Osorio, Jaime Ramos‐Cejudo, Sophia Francesca DP Lu, Andrew D. Johnson, Thomas Wısnıewskı, Alexa S. Beiser, Saptaparni Ghosh, Jeffrey S. Berger
article en

Abstract

The final primary sample included 3,169 participants (median [Q1, Q3] age, 55 [48, 61]; 54.2% women) of which 22.1% were on PMT. (Table 1). 716 (22.6%) were ApoE4 positive and 402 were E2 (16.4% of the sample after excluding E4). Being an ApoE4 carrier was not associated with platelet aggregation (β±SE: 0.41±1.05, P>0.05). ApoE2 was also not associated (-0.72±1.33, P>0.05) (Figure 1). No associations with the secondary outcomes or interactions with covariates were detected. No associations were observed in the external validation cohort (n = 2,469) CONCLUSION: Our results in a middle-aged cohort indicate that the ApoE genotypes (E2 and E4) are not associated with platelet aggregation. The pathways leading to increased vascular dysfunction in ApoE4 carriers may not involve platelet activity, at least in midlife.

Alzheimer s & DementiaVol. 20(S1)
Boston University (US), Nathan Kline Institute for Psychiatric Research (US), Institute for Neurodegenerative Disorders (US), Framingham Heart Study (US), New York University (US)
Good health and well-being
Openalex Percentile: Top 70%
Medication Adherence and Compliance
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Platelet aggregation and ApoE genotypes in the Framingham Heart Study — Sudha S. Seshadri, Matthew R. Scott, et al. · Alzheimer s & Dementia (2024) | TGRS Research Map | TGRS